What price range did the ISRG share sales occur at?

Multiple trades occurred between $542.16 and $550.21 , resulting in a weighted average of $547.5502 .

ISRG CEO Rosa sells 24,500 shares after option exercise

Q: What did ISRG’s CEO report on Form 4?

David J. Rosa exercised 27,000 options at $79.6378 and sold 24,500 shares at a $547.5502 weighted average price on 10/24/2025 .

Q: Were the ISRG stock sales under a 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 trading plan that expires on June 11, 2026 .

Q: What options did the CEO exercise?

He exercised non-qualified stock options for 27,000 shares at $79.6378 , granted under the 2010 Incentive Award Plan , expiring on 02/15/2027 .

Q: When did the ISRG insider transactions occur?

All reported transactions occurred on 10/24/2025 .

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Intuitive Surgical (ISRG) CEO David J. Rosa reported insider transactions on 10/24/2025. He exercised 27,000 non-qualified stock options at an exercise price of $79.6378 per share and sold 24,500 shares of common stock at a weighted average price of $547.5502.

The sales were executed under a Rule 10b5-1 trading plan that expires on June 11, 2026, with individual trade prices ranging from $542.16 to $550.21. Following these transactions, Rosa beneficially owns 234,256 shares directly. The exercised option, granted under the 2010 Incentive Award Plan, carries an expiration date of 02/15/2027 and vested per a stated schedule.

Insider Trade Summary

Net Seller: 24,500 shares ($13,414,980)

Net Sell 3 txns

Insider Rosa David J.

Role Chief Executive Officer (CEO)

Sold 24,500 shs ($13.41M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	27,000	$0.00	--
Exercise	Common Stock	27,000	$79.6378	$2.15M
Sale	Common Stock	24,500	$547.5502	$13.41M

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct); Common Stock — 258,756 shares (Direct)

Footnotes (1)

The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 11, 2026. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $550.21 as follows: 1,075 shares sold at $542.16 to $543.10; 1,000 shares sold at $543.23 to $544.22; 1,830 shares sold at $544.30 to $545.06; 1,300 shares sold at $545.33 to $546.15; 2,346 shares sold at $546.34 to $547.30; 6,919 shares sold at $547.37 to $548.37; 7,257 shares sold at $548.40 to $549.40; and 2,773 shares sold at $549.42 to $550.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/27/2025 - 03:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosa David J.

(Last)

(First)

(Middle)

1020 KIFER ROAD

(Street)

SUNNYVALE

94086

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer (CEO)

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/24/2025		M⁽¹⁾		27,000	A	$79.6378	258,756	D
Common Stock	10/24/2025		S⁽¹⁾		24,500	D	$547.5502⁽²⁾	234,256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$79.6378	10/24/2025		M⁽¹⁾			27,000	⁽³⁾	02/15/2027	Common Stock	27,000	$0.0	0	D

Explanation of Responses:

1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 11, 2026.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $550.21 as follows: 1,075 shares sold at $542.16 to $543.10; 1,000 shares sold at $543.23 to $544.22; 1,830 shares sold at $544.30 to $545.06; 1,300 shares sold at $545.33 to $546.15; 2,346 shares sold at $546.34 to $547.30; 6,919 shares sold at $547.37 to $548.37; 7,257 shares sold at $548.40 to $549.40; and 2,773 shares sold at $549.42 to $550.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.

	By: Stephanie Lim-Ignacio For: Rosa, David J	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ISRG’s CEO report on Form 4?

David J. Rosa exercised 27,000 options at $79.6378 and sold 24,500 shares at a $547.5502 weighted average price on 10/24/2025.

Were the ISRG stock sales under a 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 trading plan that expires on June 11, 2026.

How many ISRG shares does the CEO own after the transactions?

Following the reported transactions, Rosa beneficially owns 234,256 shares directly.

What options did the CEO exercise?

He exercised non-qualified stock options for 27,000 shares at $79.6378, granted under the 2010 Incentive Award Plan, expiring on 02/15/2027.

When did the ISRG insider transactions occur?

All reported transactions occurred on 10/24/2025.